Azienda sanitaria integrata università di Trieste
Welcome,         Profile    Billing    Logout  
 44 Trials 
72 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kim, Won Seog
ALCAMIST, NCT05148286: Albumin and Crystalloid Administration in Septic Shock

Recruiting
4
2426
RoW
Treatment, Albumin and crystalloid, Placebo, Crystalloid only
Asan Medical Center, Samsung Medical Center, Gangnam Severance Hospital, Chungnam National University Hospital, Seoul National University Hospital, Seoul National University Bundang Hospital, SMG-SNU Boramae Medical Center, Hanyang University, Korea University Ansan Hospital
Septic Shock
09/26
12/26
PROTECT-HBR, NCT04416581: Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy

Recruiting
4
3320
RoW
PPI, P-CAB 50
Duk-Woo Park, MD
Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome, Myocardial Infarction
09/26
12/27
NCT01937806: Phase 3 and Extensional Study of Besifovir

Active, not recruiting
3
197
RoW
besifovir 150mg, tenofovir 300mg
IlDong Pharmaceutical Co Ltd
Chronic Hepatitis B
02/16
01/23
PASCA, NCT04845607: Prophylactic Amiodarone for Shockable Cardiac Arrest

Recruiting
3
302
RoW
Amiodarone Injection
Won Young Kim
Cardiac Arrest, Ventricular Arrythmia
02/23
02/23
NCT05450601: A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients

Completed
3
249
RoW
HCP2102-1, HPP2104-1, HCP2102-2, HPP2104-2, RLD2106-1, HPP2103-1, RLD2106-2, HPP2103-2
Hanmi Pharmaceutical Company Limited
Hypertension
12/23
12/23
BRUIN CLL-321, NCT04666038: Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
01/27
04/28
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
05/25
04/27
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
B-Well1, NCT05630807 / 2021-005139-22: Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

Active, not recruiting
3
941
Europe, Canada, Japan, US, RoW
Bepirovirsen, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Chronic Hepatitis B, Hepatitis B, Chronic
11/25
05/26
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
NCT05067634 / 2020-005344-27: Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

Recruiting
3
140
Europe, US, RoW
Xcopri
SK Life Science, Inc.
Partial Epilepsy
05/26
07/26
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
06/25
01/28
REDIRECT, NCT04101331 / 2019-001003-20: Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides

Completed
2
108
Europe, US, RoW
AFM13
Affimed GmbH
Peripheral T Cell Lymphoma, Transformed Mycosis Fungoides
05/22
01/24
NCT02445404: Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL

Recruiting
2
134
RoW
CHOP, cyclophosphamide, cyclophosphamide, vincristine,prednisone, fractionated ICED, ifosfamide, carboplatin, etoposide, dexamethasone
Samsung Medical Center
Peripheral T-cell Lymphoma
06/22
06/23
DISTINKT, NCT04414163: A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

Active, not recruiting
2
23
RoW
IMC-001, Not confirm yet
ImmuneOncia Therapeutics Inc.
Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK/T-cell Lymphoma
07/24
02/26
NCT04921189: Steroid, Thiamine and Ascorbic Acid for Comatose Out-of-hospital Cardiac Arrest Survivors

Recruiting
2
160
RoW
The combined supplement of Ascorbic acid, Thiamine, and Cortisol, Ascorbic acid, Thiamine hcl, Cortisolu, Placebo, Normal saline
Asan Medical Center, Seoul St. Mary's Hospital, Wonju Severance Christian Hospital, Samsung Changwon Hospital, Samsung Medical Center, Chung-Ang University, Hanyang University, Ewha Womans University, Hanil General Hospital
Out-Of-Hospital Cardiac Arrest, Postcardiac Arrest Syndrome
11/24
11/25
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease

Not yet recruiting
2
393
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline
Liver Diseases, Alcoholic
12/26
03/27
Lemon-C, NCT04627753: Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.

Recruiting
2
30
RoW
Rituximab, lenalidomide, Truxima Inj, Lenalid
Kim, Seok Jin, Celltrion, Samyang Biopharmaceuticals Corporation
Primary CNS Lymphoma
11/25
11/26
B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Recruiting
2
280
Europe, Canada, Japan, US, RoW
Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo
GlaxoSmithKline
Chronic Hepatitis B Virus Infection, Hepatitis B
10/27
10/27
POTENTIAL-P, NCT06737250: NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL

Recruiting
2
33
RoW
R2P -> RP
NOBO Medicine
Primary CNS Lymphoma (PCNSL)
06/26
12/27
EPCORE DLBCL-3, NCT05660967 / 2021-005744-29: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Recruiting
2
180
Europe, Japan, US, RoW
Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/26
07/27
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211(efocipegtrutide) in Subjects

Recruiting
2
240
US, RoW
HM15211, efocipegtrutide, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/26
11/26
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
284
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
01/26
05/26
ALTAMIRA, NCT05214183: Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma

Active, not recruiting
2
81
Europe, RoW
Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma
Nordic Lymphoma Group, AstraZeneca
MCL, Mantle Cell Lymphoma
01/27
01/27
NCT03789617: A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies

Recruiting
1/2
72
RoW
EBViNT Cell, Eutil autologous blood-derived T lymphocytes
Eutilex
EBV Associated Extranodal NK/T-cell Lymphoma, EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma
09/22
12/24
KEYNOTE-877, NCT03674567: Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab

Completed
1/2
323
US, RoW
FLX475, pembrolizumab (KEYTRUDA®)
RAPT Therapeutics, Inc., Merck Sharp & Dohme LLC
Advanced Cancer
12/24
12/24
JACKPOT8, NCT04105010: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL

Completed
1/2
171
US, RoW
golidocitinib, AZD4205
Dizal Pharmaceuticals
Relapsed or Refractory Peripheral T Cell Lymphoma
10/23
02/24
SIENA, NCT06552559: Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma

Recruiting
1/2
37
RoW
Selinexor, Ifosfamide, carboplatin, etoposide, dexamethasone
Samsung Medical Center, Korean Society of Hematology
B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, CNS Metastases
12/26
12/27
NCT02580617: A Study to Evaluate the Safety of ALLO-ASC-CD for Treatment of Crohn's Disease

Recruiting
1
9
RoW
ALLO-ASC, ALLO-ASC-CD
Anterogen Co., Ltd.
Crohn's Disease
12/23
12/23
NCT04903314: Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-Onset Seizures

Recruiting
1
24
Europe, US, RoW
Xcopri
SK Life Science, Inc.
Partial Epilepsy
10/25
03/26
NCT06699771: Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

Not yet recruiting
1
48
RoW
GCC2005, Cyclophosphamide, Fludarabine
GC Cell Corporation, Artiva Biotherapeutics, Inc.
Lymphoma, T-Cell
04/26
08/27
NCT06522815: Updating Deep Learning Algorithms for OSA Monitoring

Recruiting
N/A
107
RoW
CART-I plus, Polysomnography
Sky Labs, Gangnam Severance Hospital
Obstructive Sleep Apnea, Obstructive Sleep Apnea-hypopnea
04/25
07/25
NCT02031913: Prospective Cohort Study of Association of Insulin Resistance/Steatosis With Hepatic Fibrosis in CHB and NAFLD

Completed
N/A
500
RoW
Seoul National University Boramae Hospital
Chronic Hepatitis B, Hepatic Fibrosis, Fatty Liver
11/22
12/22
NCT05386953: Intraoperative Normal Saline Administration and Acute Kidney Injury in Patients Undergoing Liver Transplantation

Recruiting
N/A
1440
RoW
Normal saline, Balanced crystalloid solution, Lactated Ringer's solution, Plasma solution
Seoul National University Hospital
End Stage Liver DIsease, Liver Transplant; Complications, Liver Cirrhosis
12/22
12/22
NCT05457114: Association Between the Use of Pulmonary Artery Catheter and Clinical Outcomes After Liver Transplantation

Recruiting
N/A
1970
RoW
Pulmonary artery catheter (Edward Lifesciences, Irvine, California, USA), FloTrac Vigileo system (EV1000 clinical platform, Edward Lifesciences, Irvine, California, USA)
Seoul National University Hospital
End Stage Liver DIsease, Liver Transplant; Complications, Liver Cirrhosis, Liver Diseases
12/22
12/22
NCT03117036: Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III

Recruiting
N/A
600
RoW
Chemotherapy, Treatment
Samsung Medical Center, Samsung Genomic Institute
Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin
12/24
12/26
NCT02206841: Establishment of NAFLD Cohort and Development of Fibrosis Markers

Recruiting
N/A
1000
RoW
Liver biopsy, ARFI, SWE, Transient elastography
Seoul National University Boramae Hospital
Fibrosis of Liver
12/29
12/30
NCT03117010: Prospective Cohort for Adult Hemophagocytosis

Recruiting
N/A
81
RoW
Steroids, Dexamethasone, Etoposide
Samsung Medical Center
Hemophagocytic Lymphohistiocytoses
12/25
12/26
LANDMARK, NCT04275726: Trial: a Randomised Controlled Trial of Myval THV

Recruiting
N/A
988
Europe, RoW
Myval THV Series, Myval/Myval Inception THVs or any subsequent advanced version commercially available at the study site., Contemporary Valves (Sapien THV Series and Evolut THV Series), Sapien THV Series (Sapien 3/Sapien 3 Ultra THVs) and Evolut THV Series (Evolut R/Evolut PRO THVs ) or any subsequent advanced version commercially available at the study site.
Meril Life Sciences Pvt. Ltd.
Aortic Valve Stenosis
03/24
12/33
AIM-CMRA, NCT05473117: iNav-based, Automated Coronary Magnetic Resonance Angiography for the Detection of Coronary Artery Stenosis

Not yet recruiting
N/A
160
Europe
Coronary Magnetic Resonance Angiography (CMRA)
Aarhus University Hospital
Coronary Artery Stenosis
12/25
12/26
NCT05124912: REMASTer: REcurrent Brain Metastases After SRS Trial

Recruiting
N/A
261
US
Radiation Therapy, Steroid Therapy, Laser Interstitial Thermal Therapy
Monteris Medical
Brain Metastases, Radiation Necrosis, Recurrent Tumor, Recurrent Metastases
12/26
10/28
NCT03183661: A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial

Recruiting
N/A
9
RoW
ALLO-ASC-CD, Allogenic adipose-derived mesenchymal stem cell
Anterogen Co., Ltd.
Crohn Disease
12/26
12/26
NCT04615091: Non-invasive Methods and Surgical Risk Stratification in Cirrhotics Undergoing Elective Extrahepatic Surgery

Recruiting
N/A
250
Europe, Canada, US, RoW
Azienda Ospedaliera Universitaria Integrata Verona
Advanced Chronic Liver Disease, Surgery--Complications
10/21
08/22
ATLAS TAVI, NCT04914481: Anatomic Stenosis Severity as a Prognostic Marker in Patients With Low-Flow Low-Gradient Aortic Stenosis Undergoing TAVI

Recruiting
N/A
1500
Europe, Canada, RoW
Universitätsklinikum Hamburg-Eppendorf, Institut universitaire de cardiologie et de pneumologie de Québec
Low-Flow, Low-Gradient Aortic Stenosis
12/22
12/25
Zaja, Francesco
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Hourglass May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
NCT04168502 / 2019-003871-20: Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

Recruiting
3
414
Europe
Gemtuzumab Ozogamicin
Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Pfizer S.R.L.
Acute Myeloid Leukemia
04/25
04/27
BRUIN CLL-321, NCT04666038: Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/25
08/26
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
05/25
04/27
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
NCT03552692 / 2017-004630-29: Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma

Terminated
2
22
Europe
Venetoclax, ABT-199/GDC-0199
Fondazione Italiana Linfomi - ETS
T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory
03/20
02/23
FIL_KLIMT, NCT03891355 / 2018-000540-25: Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL

Active, not recruiting
2
16
Europe
Carfilzomib, Lenalidomide, Dexamethasone
Fondazione Italiana Linfomi ONLUS, CELGENE, AMGEN
Mantle Cell Lymphoma
12/20
12/22
NCT04251065 / 2018-002644-91: Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH

Terminated
2
8
Europe
Daratumumab, Darzalex
Fondazione Italiana Linfomi - ETS, Janssen
Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma
12/21
11/22
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Active, not recruiting
2
75
Europe
Ibrutinib, IMBRUVICA (commercial name)
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
DLBCL
07/24
07/27
Phoenix, NCT05924100 / 2021-001538-20: Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD

Recruiting
2
22
Europe
Luspatercept Injection [Reblozyl]
Associazione Qol-one, Celgene BMS
Myelodysplastic Syndromes, Del(5Q), Anemia, Transfusion-dependent Anemia
12/24
12/29
MALIBU, NCT03697512 / 2018-002364-44: Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

Active, not recruiting
2
175
Europe
Ibrutinib, Rituximab
International Extranodal Lymphoma Study Group (IELSG), Janssen-Cilag AG, F. Hoffmann La Roche Ltd, Janssen Pharmaceutica NV
Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma
06/27
06/27
NCT04278924 / 2019-004103-12: A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

Completed
2
41
Europe, Japan, US, RoW
Placebo, TAK-079
Takeda
Primary Immune Thrombocytopenia
04/24
04/24
FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

Recruiting
2
49
Europe
Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)
Fondazione Italiana Linfomi - ETS
Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
04/26
04/29
EPCORE DLBCL-3, NCT05660967 / 2021-005744-29: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Recruiting
2
180
Europe, Japan, US, RoW
Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/26
07/27
TALIM, NCT06880601: Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma

Not yet recruiting
2
52
NA
Teclistamab
Gruppo Italiano Malattie EMatologiche dell'Adulto
Multiple Myleoma, Multiple Myeloma in Relapse, Multiple Myeloma Refractory
11/29
11/29
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Withdrawn
2
150
Europe
R-DHAP, Pola-R-DHAP
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
01/29
01/29
FIL_A-BEGEV, NCT05300282: Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

Recruiting
1/2
122
Europe
Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Relapsed or Refractory Hodgkin's Lymphoma
04/27
04/30
NCT04454580: Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy

Recruiting
N/A
15
Europe
Venetoclax, Azacitidine, Decitabine
Ospedale Maggiore Di Trieste
Acute Myeloid Leukemia, Adult, Hypomethylating Agents, Venetoclax
09/20
09/20
ICI-RT-1, NCT04419441: Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma

Recruiting
N/A
12
Europe
Immune checkpoint inhibitor, radiotherapy
Ospedale Maggiore Di Trieste
Hodgkin Lymphoma, Immune Checkpoint Inhibitor, Radiotherapy
09/20
09/20
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting
N/A
250
Europe
Ospedale di Circolo - Fondazione Macchi
SARS-CoV-2 Infection, Hematological Malignancies
10/22
10/22
ITP0918, NCT03465020: Investigation on a Dynamic Cohort of Italian Patients With Active ITP

Recruiting
N/A
861
Europe
Observation
Gruppo Italiano Malattie EMatologiche dell'Adulto, Hematology Project Foundation
Idiopathic Thrombocytopenic Purpura
07/23
07/23
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting
N/A
80
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
03/25
03/25
GIMEMA, NCT04867915: Study on the Diagnosis and Management of CLL in Italy by

Recruiting
N/A
12500
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, MBL-CLL - Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukaemia-Type
10/26
10/26
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting
N/A
1500
Europe
"novel" MAB (alone or in combination)
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Non-Hodgkin Lymphoma, B-cell
10/38
10/38
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kim, Won Seog
ALCAMIST, NCT05148286: Albumin and Crystalloid Administration in Septic Shock

Recruiting
4
2426
RoW
Treatment, Albumin and crystalloid, Placebo, Crystalloid only
Asan Medical Center, Samsung Medical Center, Gangnam Severance Hospital, Chungnam National University Hospital, Seoul National University Hospital, Seoul National University Bundang Hospital, SMG-SNU Boramae Medical Center, Hanyang University, Korea University Ansan Hospital
Septic Shock
09/26
12/26
PROTECT-HBR, NCT04416581: Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy

Recruiting
4
3320
RoW
PPI, P-CAB 50
Duk-Woo Park, MD
Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome, Myocardial Infarction
09/26
12/27
NCT01937806: Phase 3 and Extensional Study of Besifovir

Active, not recruiting
3
197
RoW
besifovir 150mg, tenofovir 300mg
IlDong Pharmaceutical Co Ltd
Chronic Hepatitis B
02/16
01/23
PASCA, NCT04845607: Prophylactic Amiodarone for Shockable Cardiac Arrest

Recruiting
3
302
RoW
Amiodarone Injection
Won Young Kim
Cardiac Arrest, Ventricular Arrythmia
02/23
02/23
NCT05450601: A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients

Completed
3
249
RoW
HCP2102-1, HPP2104-1, HCP2102-2, HPP2104-2, RLD2106-1, HPP2103-1, RLD2106-2, HPP2103-2
Hanmi Pharmaceutical Company Limited
Hypertension
12/23
12/23
BRUIN CLL-321, NCT04666038: Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
01/27
04/28
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
05/25
04/27
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
B-Well1, NCT05630807 / 2021-005139-22: Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

Active, not recruiting
3
941
Europe, Canada, Japan, US, RoW
Bepirovirsen, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Chronic Hepatitis B, Hepatitis B, Chronic
11/25
05/26
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
NCT05067634 / 2020-005344-27: Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

Recruiting
3
140
Europe, US, RoW
Xcopri
SK Life Science, Inc.
Partial Epilepsy
05/26
07/26
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
06/25
01/28
REDIRECT, NCT04101331 / 2019-001003-20: Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides

Completed
2
108
Europe, US, RoW
AFM13
Affimed GmbH
Peripheral T Cell Lymphoma, Transformed Mycosis Fungoides
05/22
01/24
NCT02445404: Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL

Recruiting
2
134
RoW
CHOP, cyclophosphamide, cyclophosphamide, vincristine,prednisone, fractionated ICED, ifosfamide, carboplatin, etoposide, dexamethasone
Samsung Medical Center
Peripheral T-cell Lymphoma
06/22
06/23
DISTINKT, NCT04414163: A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

Active, not recruiting
2
23
RoW
IMC-001, Not confirm yet
ImmuneOncia Therapeutics Inc.
Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK/T-cell Lymphoma
07/24
02/26
NCT04921189: Steroid, Thiamine and Ascorbic Acid for Comatose Out-of-hospital Cardiac Arrest Survivors

Recruiting
2
160
RoW
The combined supplement of Ascorbic acid, Thiamine, and Cortisol, Ascorbic acid, Thiamine hcl, Cortisolu, Placebo, Normal saline
Asan Medical Center, Seoul St. Mary's Hospital, Wonju Severance Christian Hospital, Samsung Changwon Hospital, Samsung Medical Center, Chung-Ang University, Hanyang University, Ewha Womans University, Hanil General Hospital
Out-Of-Hospital Cardiac Arrest, Postcardiac Arrest Syndrome
11/24
11/25
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease

Not yet recruiting
2
393
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline
Liver Diseases, Alcoholic
12/26
03/27
Lemon-C, NCT04627753: Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.

Recruiting
2
30
RoW
Rituximab, lenalidomide, Truxima Inj, Lenalid
Kim, Seok Jin, Celltrion, Samyang Biopharmaceuticals Corporation
Primary CNS Lymphoma
11/25
11/26
B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Recruiting
2
280
Europe, Canada, Japan, US, RoW
Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo
GlaxoSmithKline
Chronic Hepatitis B Virus Infection, Hepatitis B
10/27
10/27
POTENTIAL-P, NCT06737250: NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL

Recruiting
2
33
RoW
R2P -> RP
NOBO Medicine
Primary CNS Lymphoma (PCNSL)
06/26
12/27
EPCORE DLBCL-3, NCT05660967 / 2021-005744-29: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Recruiting
2
180
Europe, Japan, US, RoW
Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/26
07/27
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211(efocipegtrutide) in Subjects

Recruiting
2
240
US, RoW
HM15211, efocipegtrutide, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/26
11/26
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
284
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
01/26
05/26
ALTAMIRA, NCT05214183: Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma

Active, not recruiting
2
81
Europe, RoW
Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma
Nordic Lymphoma Group, AstraZeneca
MCL, Mantle Cell Lymphoma
01/27
01/27
NCT03789617: A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies

Recruiting
1/2
72
RoW
EBViNT Cell, Eutil autologous blood-derived T lymphocytes
Eutilex
EBV Associated Extranodal NK/T-cell Lymphoma, EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma
09/22
12/24
KEYNOTE-877, NCT03674567: Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab

Completed
1/2
323
US, RoW
FLX475, pembrolizumab (KEYTRUDA®)
RAPT Therapeutics, Inc., Merck Sharp & Dohme LLC
Advanced Cancer
12/24
12/24
JACKPOT8, NCT04105010: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL

Completed
1/2
171
US, RoW
golidocitinib, AZD4205
Dizal Pharmaceuticals
Relapsed or Refractory Peripheral T Cell Lymphoma
10/23
02/24
SIENA, NCT06552559: Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma

Recruiting
1/2
37
RoW
Selinexor, Ifosfamide, carboplatin, etoposide, dexamethasone
Samsung Medical Center, Korean Society of Hematology
B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, CNS Metastases
12/26
12/27
NCT02580617: A Study to Evaluate the Safety of ALLO-ASC-CD for Treatment of Crohn's Disease

Recruiting
1
9
RoW
ALLO-ASC, ALLO-ASC-CD
Anterogen Co., Ltd.
Crohn's Disease
12/23
12/23
NCT04903314: Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-Onset Seizures

Recruiting
1
24
Europe, US, RoW
Xcopri
SK Life Science, Inc.
Partial Epilepsy
10/25
03/26
NCT06699771: Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

Not yet recruiting
1
48
RoW
GCC2005, Cyclophosphamide, Fludarabine
GC Cell Corporation, Artiva Biotherapeutics, Inc.
Lymphoma, T-Cell
04/26
08/27
NCT06522815: Updating Deep Learning Algorithms for OSA Monitoring

Recruiting
N/A
107
RoW
CART-I plus, Polysomnography
Sky Labs, Gangnam Severance Hospital
Obstructive Sleep Apnea, Obstructive Sleep Apnea-hypopnea
04/25
07/25
NCT02031913: Prospective Cohort Study of Association of Insulin Resistance/Steatosis With Hepatic Fibrosis in CHB and NAFLD

Completed
N/A
500
RoW
Seoul National University Boramae Hospital
Chronic Hepatitis B, Hepatic Fibrosis, Fatty Liver
11/22
12/22
NCT05386953: Intraoperative Normal Saline Administration and Acute Kidney Injury in Patients Undergoing Liver Transplantation

Recruiting
N/A
1440
RoW
Normal saline, Balanced crystalloid solution, Lactated Ringer's solution, Plasma solution
Seoul National University Hospital
End Stage Liver DIsease, Liver Transplant; Complications, Liver Cirrhosis
12/22
12/22
NCT05457114: Association Between the Use of Pulmonary Artery Catheter and Clinical Outcomes After Liver Transplantation

Recruiting
N/A
1970
RoW
Pulmonary artery catheter (Edward Lifesciences, Irvine, California, USA), FloTrac Vigileo system (EV1000 clinical platform, Edward Lifesciences, Irvine, California, USA)
Seoul National University Hospital
End Stage Liver DIsease, Liver Transplant; Complications, Liver Cirrhosis, Liver Diseases
12/22
12/22
NCT03117036: Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III

Recruiting
N/A
600
RoW
Chemotherapy, Treatment
Samsung Medical Center, Samsung Genomic Institute
Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin
12/24
12/26
NCT02206841: Establishment of NAFLD Cohort and Development of Fibrosis Markers

Recruiting
N/A
1000
RoW
Liver biopsy, ARFI, SWE, Transient elastography
Seoul National University Boramae Hospital
Fibrosis of Liver
12/29
12/30
NCT03117010: Prospective Cohort for Adult Hemophagocytosis

Recruiting
N/A
81
RoW
Steroids, Dexamethasone, Etoposide
Samsung Medical Center
Hemophagocytic Lymphohistiocytoses
12/25
12/26
LANDMARK, NCT04275726: Trial: a Randomised Controlled Trial of Myval THV

Recruiting
N/A
988
Europe, RoW
Myval THV Series, Myval/Myval Inception THVs or any subsequent advanced version commercially available at the study site., Contemporary Valves (Sapien THV Series and Evolut THV Series), Sapien THV Series (Sapien 3/Sapien 3 Ultra THVs) and Evolut THV Series (Evolut R/Evolut PRO THVs ) or any subsequent advanced version commercially available at the study site.
Meril Life Sciences Pvt. Ltd.
Aortic Valve Stenosis
03/24
12/33
AIM-CMRA, NCT05473117: iNav-based, Automated Coronary Magnetic Resonance Angiography for the Detection of Coronary Artery Stenosis

Not yet recruiting
N/A
160
Europe
Coronary Magnetic Resonance Angiography (CMRA)
Aarhus University Hospital
Coronary Artery Stenosis
12/25
12/26
NCT05124912: REMASTer: REcurrent Brain Metastases After SRS Trial

Recruiting
N/A
261
US
Radiation Therapy, Steroid Therapy, Laser Interstitial Thermal Therapy
Monteris Medical
Brain Metastases, Radiation Necrosis, Recurrent Tumor, Recurrent Metastases
12/26
10/28
NCT03183661: A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial

Recruiting
N/A
9
RoW
ALLO-ASC-CD, Allogenic adipose-derived mesenchymal stem cell
Anterogen Co., Ltd.
Crohn Disease
12/26
12/26
NCT04615091: Non-invasive Methods and Surgical Risk Stratification in Cirrhotics Undergoing Elective Extrahepatic Surgery

Recruiting
N/A
250
Europe, Canada, US, RoW
Azienda Ospedaliera Universitaria Integrata Verona
Advanced Chronic Liver Disease, Surgery--Complications
10/21
08/22
ATLAS TAVI, NCT04914481: Anatomic Stenosis Severity as a Prognostic Marker in Patients With Low-Flow Low-Gradient Aortic Stenosis Undergoing TAVI

Recruiting
N/A
1500
Europe, Canada, RoW
Universitätsklinikum Hamburg-Eppendorf, Institut universitaire de cardiologie et de pneumologie de Québec
Low-Flow, Low-Gradient Aortic Stenosis
12/22
12/25
Zaja, Francesco
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Hourglass May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
NCT04168502 / 2019-003871-20: Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

Recruiting
3
414
Europe
Gemtuzumab Ozogamicin
Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Pfizer S.R.L.
Acute Myeloid Leukemia
04/25
04/27
BRUIN CLL-321, NCT04666038: Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/25
08/26
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
05/25
04/27
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
NCT03552692 / 2017-004630-29: Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma

Terminated
2
22
Europe
Venetoclax, ABT-199/GDC-0199
Fondazione Italiana Linfomi - ETS
T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory
03/20
02/23
FIL_KLIMT, NCT03891355 / 2018-000540-25: Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL

Active, not recruiting
2
16
Europe
Carfilzomib, Lenalidomide, Dexamethasone
Fondazione Italiana Linfomi ONLUS, CELGENE, AMGEN
Mantle Cell Lymphoma
12/20
12/22
NCT04251065 / 2018-002644-91: Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH

Terminated
2
8
Europe
Daratumumab, Darzalex
Fondazione Italiana Linfomi - ETS, Janssen
Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma
12/21
11/22
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Active, not recruiting
2
75
Europe
Ibrutinib, IMBRUVICA (commercial name)
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
DLBCL
07/24
07/27
Phoenix, NCT05924100 / 2021-001538-20: Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD

Recruiting
2
22
Europe
Luspatercept Injection [Reblozyl]
Associazione Qol-one, Celgene BMS
Myelodysplastic Syndromes, Del(5Q), Anemia, Transfusion-dependent Anemia
12/24
12/29
MALIBU, NCT03697512 / 2018-002364-44: Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

Active, not recruiting
2
175
Europe
Ibrutinib, Rituximab
International Extranodal Lymphoma Study Group (IELSG), Janssen-Cilag AG, F. Hoffmann La Roche Ltd, Janssen Pharmaceutica NV
Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma
06/27
06/27
NCT04278924 / 2019-004103-12: A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

Completed
2
41
Europe, Japan, US, RoW
Placebo, TAK-079
Takeda
Primary Immune Thrombocytopenia
04/24
04/24
FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

Recruiting
2
49
Europe
Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)
Fondazione Italiana Linfomi - ETS
Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
04/26
04/29
EPCORE DLBCL-3, NCT05660967 / 2021-005744-29: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Recruiting
2
180
Europe, Japan, US, RoW
Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/26
07/27
TALIM, NCT06880601: Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma

Not yet recruiting
2
52
NA
Teclistamab
Gruppo Italiano Malattie EMatologiche dell'Adulto
Multiple Myleoma, Multiple Myeloma in Relapse, Multiple Myeloma Refractory
11/29
11/29
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Withdrawn
2
150
Europe
R-DHAP, Pola-R-DHAP
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
01/29
01/29
FIL_A-BEGEV, NCT05300282: Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

Recruiting
1/2
122
Europe
Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Relapsed or Refractory Hodgkin's Lymphoma
04/27
04/30
NCT04454580: Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy

Recruiting
N/A
15
Europe
Venetoclax, Azacitidine, Decitabine
Ospedale Maggiore Di Trieste
Acute Myeloid Leukemia, Adult, Hypomethylating Agents, Venetoclax
09/20
09/20
ICI-RT-1, NCT04419441: Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma

Recruiting
N/A
12
Europe
Immune checkpoint inhibitor, radiotherapy
Ospedale Maggiore Di Trieste
Hodgkin Lymphoma, Immune Checkpoint Inhibitor, Radiotherapy
09/20
09/20
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting
N/A
250
Europe
Ospedale di Circolo - Fondazione Macchi
SARS-CoV-2 Infection, Hematological Malignancies
10/22
10/22
ITP0918, NCT03465020: Investigation on a Dynamic Cohort of Italian Patients With Active ITP

Recruiting
N/A
861
Europe
Observation
Gruppo Italiano Malattie EMatologiche dell'Adulto, Hematology Project Foundation
Idiopathic Thrombocytopenic Purpura
07/23
07/23
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting
N/A
80
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
03/25
03/25
GIMEMA, NCT04867915: Study on the Diagnosis and Management of CLL in Italy by

Recruiting
N/A
12500
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, MBL-CLL - Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukaemia-Type
10/26
10/26
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting
N/A
1500
Europe
"novel" MAB (alone or in combination)
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Non-Hodgkin Lymphoma, B-cell
10/38
10/38

Download Options